Pharmaceutical companies that saw antitrust litigation against them revived by the U.S. Supreme Court last year are asking a federal judge in Atlanta to allow another them another shot at an appeal to keep so-called “pay-for-delay” deals alive.
After the seven-year-old antitrust case involving the maker of the male hormone booster AndroGel landed back in U.S. District Judge Thomas Thrash Jr.’s Atlanta courtroom, Thrash last month refused to do what he did in 2010—dismiss it. That prompted a renewed effort this month by the defendant pharmaceutical firms to appeal the case.
